CHMP Grants Positive Opinion for Kaftiro + Kalydecofor cystic fibrosis patients with the most common genotypes

Vertex Pharmaceutical said on Friday in a press release that, if Kaftrio combined with Kalydeco is granted Marketing Authorization, people ages 12 and older in Europe who have one F508del mutation and one minimal function mutation will for the first time be able to benefit from a medicine that treats the underlying cause of the disease.

Read more